Table 2.
Demographic data: once weekly versus once every 3 weeks darbepoetin alfa administration
| Demographic | qw ESA administration group | q3w ESA administration group | P value |
|---|---|---|---|
| Number of patients | 83 | 112a | |
| Age, years (SD) | 59.5 (9.8) | 62.3 (13.3) | NS |
| Gender | |||
| Male | 20 (24.1) | 18 (16.1) | NS |
| Female | 63 (75.9) | 94 (83.9) | NS |
| Ethnicity | |||
| Unknown | 1 (1.2) | 5 (4.5) | NS |
| Hispanic or Latino | 3 (3.6) | 0 | NS |
| Not Hispanic or Latino | 79 (95.2) | 107 (95.5) | NS |
| Cancer type | |||
| Lung | 27 (32.5) | 23 (20.5) | NS |
| Ovarian | 12 (14.5) | 36 (32.1) | 0.0056 |
| Colorectal | 13 (15.7) | 6 (5.4) | 0.0216 |
| Prostate | 2 (2.4) | 3 (2.7) | NS |
| Lymphoma | 6 (7.2) | 11 (9.8) | NS |
| Metastatic breast | 15 (18.1) | 25 (22.3) | NS |
| Metastatic head/neck | 7 (8.4) | 2 (1.8) | 0.0466 |
| Lung, metastatic breast | 0 | 1 (0.9) | NS |
| Lung, metastatic head/neck | 1 (1.2) | 1 (0.9) | NS |
| Ovarian, lymphoma | 0 | 4 (3.6) | NS |
| Duration of ESA therapy in days [mean (SD)] | 53.84 (55.46) | 113.38 (83.81) | <0.0001 |
Values are presented as n (%) unless specified otherwise
ESA erythropoiesis-stimulating agent, NS non-significant, q3w once every 3 weeks, qw once weekly
aSite 1 subject 50 was excluded due to excessive visitation frequency (257 visits)